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Abstract Transcatheter aortic valve implantation is in-
creasingly used to treat patients with severe aortic stenosis
who are at increased risk for surgical aortic valve replace-
ment and is projected to be the preferred treatment modal-
ity. As patient selection and operator experience have im-
proved, it is hypothesised that device-host interactions will
play a more dominant role in outcome. This, in combination
with the increasing number of valve types and sizes, con-
fronts the physician with the dilemma to choose the valve
that best fits the individual patient. This necessitates the
availability of pre-procedural computer simulation that is
based upon the integration of the patient-specific anatomy,
the physical and (bio)mechanical properties of the valve
and recipient anatomy derived from in-vitro experiments.
The objective of this paper is to present such a model and
illustrate its potential clinical utility via a few case studies.
Keywords Aortic valve stenosis · Transcatheter aortic
valve implantation · Computer simulation
Introduction
Transcatheter aortic valve implantation (TAVI) is increas-
ingly used to treat patients with severe aortic stenosis who
are at increased risk for surgical aortic valve replacement
(SAVR) and is projected to be the preferred treatment
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modality in patients who are at intermediate and suppos-
edly low risk [1–4]. Similar to any other treatment that
consists of the implantation of a device into the human
body or circulation, outcome depends on specific device-
host related factors in addition to patient- and procedure/
operator-related variables [5]. Device-host interactions in-
volve the interactions between the patient and device that
invariably occur independent of operator-related ones and
which affect valve configuration immediately after delivery
and, therefore, function and ultimately clinical outcome.
Device-host interactions may in particular play a role
in valve performance and outcome after TAVI since – at
variance with SAVR – the calcium at the base of aortic
root including leaflets is not excised. Therefore, incomplete
and/or non-uniform expansion of the frame can occur that
in turn may lead to paravalvular leakage (PVL) or a residual
gradient [5–8]. Also, the frame extends into the left ventric-
ular outflow tract (LVOT) and may, depending on the depth
of implantation in combination with sizing, induce a vary-
ing degree of contact stress on the LVOT that in turn may
contribute to the occurrence of conduction disturbances [9].
Both conditions are of clinical importance since, depending
on the patient’s baseline risk, they may be associated with
impaired prognosis [10–12]. Novel generation devices have
to a large extent addressed the issue of PVL but are associ-
ated with a higher incidence of conduction abnormalities in
comparison to preceding valve designs [13, 14]. Yet, PVL
still occurs and a number of other (rare) complications can
happen such as aortic root rupture, coronary obstruction or
valve embolisation [15–18].
On one hand, there is a substantial increase in experience
with TAVI that in turn has improved outcome [19, 20]. On
the other, the number of different types and sizes of valve
technologies increase as well [21]. It is therefore conceiv-
able that device-host interactions will play a dominant role
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Fig. 1 MSCT and 3D recon-
struction aortic root and the
Medtronic CoreValve with mi-
croCT
Fig. 2 Observed (MSCT post-
TAVI) and predicted (computer
simulation) valve geometry with
correlation between MSCT and
predicted maximal diameter
(Dmax) [25]
in clinical outcome and that, therefore, the selection of the
valve that best fits the individual patient will play a more
important role in the further improvement of outcome of
TAVI. Such a patient-specific approach – which is endorsed
by society and health care policy makers – necessitates the
availability of pre-procedural computer simulation that is
based upon the integration of the patient-specific anatomy,
the physical and (bio)mechanical properties of the valve
and recipient anatomy derived from in-vitro experiments
[22–24]. The objective of this paper is to present such
a model and illustrate its potential clinical utility via a few
case studies.
Methods and results
Computer simulation with TAVIguide – concept and
workflow
Concept
Simulation of the implantation of a device into the human
body implies the integration of both the physical dimensions
and properties of the device (i. e. material) and host (i. e.
tissue). The dimensions of device and host are easy to col-
lect (technical information on file, 3D imaging). This also
holds for the mechanical properties of the device (mechan-
ical testing) but not for the tissue properties of the patient.
In the TAVIguide framework, these tissue properties have
been calibrated during initial clinical evaluation studies by
using pre- and post-TAVI multislice computed tomography
(MSCT) images [25]. The following workflow is (to be)
followed:
Patient anatomy
MSCT is used to obtain geometric and quantitative infor-
mation on the aortic root using a dedicated scanning and
analysis protocol that will be used for 3D reconstruction of
the aortic root for subsequent simulation (Fig. 1).
Device
As valves are implanted virtually, finite element computer
models of valve frames are first developed based upon phys-
ical dimensions using microCT, microscopic measurements
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Fig. 3 Comparison between
MSCT and the predicted dis-
tance between the coronary ostia
and the closest calcium nodule
with correlation between MSCT
and predicted distance from the
coronary ostia to the calcium
nodule [25]
Fig. 4 Blood flow domains including PVL channels were derived from predicted frame deformation and box plot analysis from the observed and
predicted PVL [26]
(resolution of 30 micron, Fig. 1) and mechanical properties.
For the latter, in-vitro radial compression tests at body tem-
perature are performed during which the diameter of the
frame is reduced over its full length by segmental com-
pression mechanism while recording radial force (RX650,
Machine Solutions, Flagstaff, US).
Computer modelling
Patient-specific 3D computer models of the aortic root in-
cluding the calcified native leaflets are reconstructed using
MSCT and image segmentation techniques (Mimics Soft-
ware, Materialise, Leuven, Belgium). Varying mechanical
properties are automatically assigned to different tissue re-
gions within the LVOT-aortic root complex. The biome-
chanical properties used in the TAVIguide simulations are
improved by calibration and validation studies [25]. The
computer generated valve frames are then implanted virtu-
ally into the patient’s specific anatomy using finite element
computer simulations using the Abaqus/Explicit finite ele-
ment solver (Dassault Systèmes, Paris, France).
Clinical validation
Two multicentre observational studies have been conducted
for the clinical validation of the TAVIguide software [25,
26]. The first sought to assess the accuracy of the soft-
ware to predict frame morphology, dimensions and aortic
leaflet displacement after valve implantation [25]. Quan-
titative data of axial frame morphology (minimal diame-
ter (Dmin), maximal diameter (Dmax), cross-sectional area
and perimeter) of 33 patients treated with the Medtronic
CoreValve System (MCS) and of 6 patients treated with the
Edwards Sapien XT (ESV) obtained by MSCT post-TAVI
(observed frame morphology & dimensions), were com-
pared with those obtained from the computer model (pre-
dicted frame morphology & dimensions) (Fig. 2). Similarly,
displacement of the aortic leaflet calcifications, quantified
by the distance between the coronary ostia and the closest
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Fig. 5 a change in depth of implantation; lower implant resulted in
less PVL. b change in valve size; a larger valve resulted in a reduction
of PVL. c change in valve type without changing size and implantation
depth: significant less PVL after Evolut R implantation
calcium nodule, was compared between MSCT and model
(Fig. 3).
During the simulation, all steps of the clinical TAVI
procedure were respected including pre-dilatation, valve
size, depth of implantation and post-dilatation if applied.
The depth of implantation was matched with the depth of
implantation during actual valve implantation by overlay-
ing the 3D aortic root model derived from the software
after simulation of valve implantation with the one derived
from MSCT post-TAVI followed by evaluating the result-
ing alignment of the inflow of the valve frame of the 3D
model with the one of the MSCT post-TAVI, which was
used as reference. Simulations were repeated until correct
alignment was obtained, which was used for the validation
analysis. For the pre- and (if applicable) post-dilatation, the
same size of the balloon that was used during the in-vivo
implantation was used during the computer simulation.
Bland-Altman analysis revealed a strong correlation be-
tween the observed (MSCT) and predicted frame dimen-
sions although small differences were detected for e. g.
Dmin at the inflow (mean ± SD, MSCT vs. model: 21.6 ±
2.4 mm vs. 22.0 ± 2.4 mm; difference ± SD: –0.4 ± 1.3 mm,
p < 0.05) and Dmax (mean ± SD, 25.6 ± 2.7 mm vs. 26.2 ±
2.7 mm; difference ± SD: –0.6 ± 1.0 mm, p < 0.01). An
example of the correlation between the observed and pre-
dicted Dmax is shown in Fig. 2. The observed and predicted
distances from coronary ostia to the closest calcium nodule
were highly correlated for the left and right coronary ostia
(R2 = 0.67 and R2 = 0.71, respectively p < 0.001) (Fig. 3).
This distance was slightly overestimated by the model for
both coronary arteries. Dedicated software, thus, allows
accurate prediction of frame morphology and calcium dis-
placement after valve implantation, which may help to im-
prove outcome.
The second study focused on the accuracy of the model
for the prediction of PVL after TAVI [26]. Similar to the
first validation study, pre-operative MSCT was used to gen-
erate 3D models of the aortic root of 60 patients treated with
a MCS valve. Implantation of virtual valve models was
simulated using finite element computer modelling. Blood
flow domains including PVL channels were derived from
predicted frame and aortic root deformation (Fig. 4). Com-
putational fluid dynamics was used to model blood flow
during diastole to assess PVL. Predicted and observed PVL
(angiography, echocardiography) were compared. Moder-
ate or more PVL was seen in 15 patients (25%) by an-
giography (Sellers aortic regurgitation grade ≥2) and in 9
(15%) by echocardiography (short-axis circumferential ex-
tent ≥10%, VARC-2). Box plot analysis revealed good
agreement between observed and predicted PVL (Fig. 4).
ROC analysis indicated 16.25 ml/sec (reference angiogra-
phy) and 16.0 ml/sec (reference echocardiography) as cut-
off values that best differentiated patients with none-to-mild
and moderate-to-severe PVL. Sensitivity, specificity, posi-
tive predictive value, negative predictive value and accuracy
were 0.80, 0.80, 0.57, 0.92 and 0.80, respectively (reference
angiography) and were 0.72, 0.78, 0.35, 0.94 and 0.73 (ref-
erence echocardiography).
Case studies
The clinical role and potential of computer simulation is il-
lustrated by case examples in which depth of implantation,
valve size or valve type have been changed while using
the same baseline anatomy (i. e. MSCT patient) to assess
the effect of those changes on PVL (Fig. 5). Implanting
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a 26 mm MCS in a lower position resulted in a 87% reduc-
tion in PVL. Using the same implantation depth but a 29
instead of a 26 mm valve resulted in a 26% reduction in
PVL. Changing valve type while maintaining similar im-
plantation depth and valve size did have an effect of 53%
reduction in PVL when using the Evolut R valve instead of
the MCS.
Discussion
Outcome of a medical intervention such as TAVI depends
on a combination of patient-, procedure- or operator- and
device-related factors, each of which contributes to out-
come in a different way and magnitude. As the outcome of
TAVI improves due to improved patient selection and op-
erator performance, it is hypothesised that the interaction
between device and host will play a more dominant role.
Obviously, valve technology changes and improves as well,
yet clinical issues will remain as a prosthesis is implanted
in a very specific biological environment that necessitates
a patient-customised valve that unfortunately does not exist.
In clinical practice, however, the physician has the choice
between an increasing number of valve types and sizes that
in turn confronts him/her with the responsibility to choose
the valve that best fits the individual patient. To support
the physician in this process, simulation of valve implanta-
tion such as the one that is described here is a novel and
reachable step forward.
The simulation presented above has shown in a selected
series of patients and centres that computer simulation with
the TAVIguide accurately predicts frame geometry, aortic
leaflet calcium displacement and, thus, risk of coronary
KEY MESSAGE Computer simulation (3D) – by means of CT – has the ability to accurately predict frame geometry, 
aortic leaflet calcium displacement and paravalvular leakage after TAVI. This could support the 
physician in the process of a patient specific approach with regards to the decision of valve type 
and -size and thereby potentially reduce complications after TAVI.
occlusion in addition to PVL directly after MCS and ESV
implantation [25, 26]. Also, the versatility of the program
is illustrated with the case studies in which the effect of
changing either the depth of implantation, valve size or
type in the same patient on the severity of PVL is shown.
As mentioned, the information stems from a selected se-
ries of patients in centres that perform high-quality MSCT
in all their patients referred for TAVI. It remains to be
seen whether similar correlations as reported in the two
pilot observational studies will be observed when offering
computer simulation to a wider range of patients and cen-
tres with varying degrees of access to MSCT and MSCT
image quality. Also, the current computer simulation pro-
gram only offers simulation for a limited number of valve
types. This implies that the development of software for
computer simulation is a continuous process in which novel
valve technologies have to be incorporated into the software
algorithm. In addition, as novel generation valves appear to
have addressed the issue of PVL, other interactions – con-
duction abnormalities in particular – need to be predicted
by the simulation program. For instance, the incidence
of moderate or severe aortic regurgitation after Lotus and
Edwards Sapien 3 valve implantation is 1% but are asso-
ciated with a new pacemaker implantation rate of 32 and
17%, respectively [13, 14].
In addition to the incorporation of all clinically available
valve technologies and the capacity to predict all clinically
relevant (i. e. frequency and severity) device-host inter-
actions, the clinical role of the computer simulation pro-
gram needs to be further established by appropriately de-
signed prospective and ultimately randomised clinical trials
in a wide segment of patients scheduled for TAVI.
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The development of patient-specific treatment and treat-
ment planning (patient-tailored approach) is strongly rec-
ommended by the health care authorities and is also more
and more embraced by the medical community [27]. More
specifically, to evaluate its effectiveness in clinical practice,
a European multicentre study is currently being designed.
The multicentre character reflects the interest of the med-
ical community in this program. With respect to logistics,
time and costs, only a MSCT scan needs to be uploaded
via a web-based system that is followed by simulation with
a written report within 24–48 h. Costs are not defined yet
and will ultimately depend on the ratio of input, volume
and eventual benefit.
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